gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · GERNHealthcarePharmaceuticals

Geron Corp (GERN)

$1.08+16.13%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$0.93▼ 22.57% in range
Nov 3, 2025Low $0.89 · High $1.95Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

Geron closed at $1.08 on Nov 4, up 16.13%, 44.6% below its 52-week closing high. Volume of 26.8M shares was 1.75× its 20-day average (above normal).

Split-adjusted performance: -10.7% over one month, -31.6% over six months, -10.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $57.48M, up 17.2% from a year earlier, with a net margin of -29.0%.

Short interest was 74.6M shares at the Oct 15 settlement (11.9% of float, 9.9 days to cover).

Market cap$693.9M642.5M shares
Revenue · quarter$57.5M+17.2% YoY
Diluted EPS$-0.02—
P/E · TTM—P/S 3.4×
Net margin-29.0%Gross 83.9%
Dividend yieldNone
52-week range0.89 – 1.95−44.6% from high
Volume26.8M1.75× 20-day avg
Volatility · 60d64.6%Annualised
Short % of float11.9%9.9 days to cover
Net cash$51.1MCash $300.8M
Next earnings—Not scheduled
Split-adjusted performance
1W +11.5%1M −10.7%3M −31.2%6M −31.6%YTD −18.2%1Y −10.0%3Y −43.5%5Y −25.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum43
Revenue growth64
Net margin52
Value (low P/E)—
Size66

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short74.6M+1.0% vs prior
Days to cover9.9Settled Oct 15
% of float11.9%
Short vol. 10d50.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
GERNGeron$1.08+16.13%−31.6%+17.2%−29.0%—$693.9M
SGMTSagimet Biosciences Inc. Series A$9.99+0.40%+19.2%———$708.4MCompare
OBXObsidian Therapeutics$10.99−16.93%————$678.9MCompare
KURAKura Oncology$7.61−22.98%−20.4%+36.5%−327.3%—$677.0MCompare
WVEWave Life Sciences$3.62+1.12%−50.3%+72.9%−470.5%—$714.0MCompare
DSGNDesign Therapeutics$10.63+2.80%−26.9%———$665.2MCompare
AVBPArriVent BioPharma$13.49+3.61%−54.5%———$665.2MCompare
ZVRAZevra Therapeutics$11.17+8.87%−0.7%+44.9%48.8%8.6$663.3MCompare
IMMXImmix Biopharma$7.97+3.37%−22.8%———$660.7MCompare

News about Geron

All news →
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswire Inc. · Oct 21, 2026▲ PositiveGeron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026GlobeNewswire Inc. · Apr 22, 2026NeutralGeron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate SecretaryGlobeNewswire Inc. · Apr 13, 2026▲ PositiveGeron to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire Inc. · Apr 6, 2026NeutralGeron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewswire Inc. · Feb 25, 2026Neutral

Quick answers

What does Geron do?
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.
What is GERN's market cap?
$693.87M, based on the Nov 4 close of $1.08.
Does Geron pay a dividend?
No regular cash dividend has been paid in the last year.
How much of GERN is sold short?
74.6M shares, 11.9% of float, as of Oct 15, 2026.
What sector is GERN in?
Healthcare, in the Pharmaceuticals industry.

About Geron

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

HQ: Foster City, CA258 employeesListed Jul 31, 1996geron.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology